Redmile Group, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001425738
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 40 positions · Total reported value $1.03B · Top-10 concentration 68.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 69.2% · 4 new · 23 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +21.6% · vs SPY +6.8% · Prev Value $1.51B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2025 13F filing, Redmile Group, LLC disclosed 40 equity positions with a combined reported value of $1.03B. The filing implies a focused portfolio: its ten largest positions account for 68.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were SRRK ($145.40M), KRYS ($116.75M), STOK ($98.13M). By sector, the heaviest allocations are Health Care 91.5%, Other 8.5%. Versus the prior quarter, allocation shifted toward Health Care (+2.5pp) and away from Other (-0.8pp), Technology (-1.7pp).
Versus the prior quarter, Redmile Group, LLC opened 4 new positions, trimmed 23 and fully exited 0, a turnover rate of 69.2% of positions. The portfolio's overlap with the prior quarter was 83% of names.
Of the 8 positions fully exited versus the prior quarter, the largest were KYMR ($35.06M), HNGE ($15.53M), BHVN ($10.29M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
No new positions this quarter.
Fully Exited (vs previous quarter)
- KYMR KYMERA THERAPEUTICS INC · prev qtr: $35.06M
- HNGE HINGE HEALTH INC · prev qtr: $15.53M
- BHVN BIOHAVEN LTD · prev qtr: $10.29M
- BSX BOSTON SCIENTIFIC CORP · prev qtr: $9.16M
- VERV VERVE THERAPEUTICS INC · prev qtr: $8.31M
- PEN PENUMBRA INC · prev qtr: $4.83M
- IGMS IGM BIOSCIENCES INC · prev qtr: $3.31M
- FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $416.14K
Insider Transactions (Form 4)
Latest Redmile Group, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-06 | Buy | Attovia Therapeutics, Inc. | 400,000 | $17.00 | SEC filing |
| 2026-08-06 | Buy | Attovia Therapeutics, Inc. | 200,000 | $17.00 | SEC filing |
| 2026-08-06 | Conversion | Attovia Therapeutics, Inc. | 782,854 | — | SEC filing |
| 2026-07-22 | Tax payment | Atara Biotherapeutics, Inc. | 60 | — | SEC filing |
| 2026-07-22 | Opt exercise | Atara Biotherapeutics, Inc. | 195,211 | — | SEC filing |
| 2026-04-20 | J | FATE THERAPEUTICS INC | 8,977,624 | — | SEC filing |
Fund Profile
Redmile Group, LLC, based in Larkspur, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $1.49B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: LARKSPUR, CA, United States
- SEC registration: 801-67747 (status: Approved), registered 2007-04-19
- Regulatory AUM (Form ADV): $4.70B as of 2026-08-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 20 private funds, of which 10 hedge funds
- Website: redmilegroup.com
Portfolio Structure
- 39 positions · $1.49B reported value (Q2 2026)
- Top 10 holdings = 73.5% of reported value
- Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 15.9%
- Average position size: $38.19M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 5 added, 23 reduced
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.90M | $145.40M | 14.15% | Reduce | |
| 2 |
|
661.39K | $116.75M | 11.36% | Hold | |
| 3 |
|
4.18M | $98.13M | 9.55% | Reduce | |
| 4 |
|
3.71M | $63.29M | 6.16% | Reduce | |
| 5 |
|
15.67M | $62.67M | 6.10% | Hold | |
| 6 |
|
5.02M | $58.82M | 5.72% | Add | |
| 7 |
|
926.80K | $48.55M | 4.72% | Reduce | |
| 8 |
|
4.69M | $45.29M | 4.41% | Reduce | |
| 9 |
|
747.82K | $35.51M | 3.46% | Reduce | |
| 10 |
|
3.68M | $33.99M | 3.31% | Reduce | |
| 11 |
|
1.39M | $33.68M | 3.28% | Reduce | |
| 12 |
|
2.21M | $31.72M | 3.09% | Add | |
| 13 |
|
8.25M | $25.09M | 2.44% | Hold | |
| 14 |
|
1.30M | $22.51M | 2.19% | Add | |
| 15 |
|
1.47M | $21.66M | 2.11% | Reduce | |
| 16 |
|
742.02K | $20.19M | 1.96% | Add | |
| 17 |
|
6.30M | $19.22M | 1.87% | Hold | |
| 18 |
|
12.87M | $16.22M | 1.58% | Hold | |
| 19 |
|
552.59K | $14.25M | 1.39% | Reduce | |
| 20 |
|
5.54M | $13.24M | 1.29% | Hold | |
| 21 |
|
1.90M | $11.72M | 1.14% | Reduce | |
| 22 |
|
2.16M | $11.24M | 1.09% | Hold | |
| 23 |
|
3.03M | $11.21M | 1.09% | Hold | |
| 24 |
|
552.51K | $8.74M | 0.85% | Hold | |
| 25 |
|
327.01K | $8.46M | 0.82% | Reduce | |
| 26 |
|
441.70K | $6.33M | 0.62% | Hold | |
| 27 |
|
777.18K | $6.12M | 0.60% | Reduce | |
| 28 |
|
3.33M | $6.10M | 0.59% | Reduce | |
| 29 |
|
129.36K | $5.30M | 0.52% | Reduce | |
| 30 |
|
435.24K | $5.00M | 0.49% | Hold | |
| 31 |
|
451.10K | $3.67M | 0.36% | Hold | |
| 32 |
|
1.07M | $3.34M | 0.33% | Reduce | |
| 33 |
|
2.07M | $3.24M | 0.32% | Hold | |
| 34 |
|
1.59M | $2.79M | 0.27% | Hold | |
| 35 |
|
2.29M | $2.51M | 0.24% | Hold | |
| 36 |
|
1.59M | $2.36M | 0.23% | Reduce | |
| 37 |
|
535.82K | $2.25M | 0.22% | Reduce | |
| 38 |
|
87.12K | $482.63K | 0.05% | Reduce | |
| 39 |
|
82.95K | $479.48K | 0.05% | Hold | |
| 40 |
|
245.46K | $301.91K | 0.03% | Reduce | |
FAQ
What did Redmile Group, LLC buy in 2025-Q3?
In its 2025-Q3 13F filing, Redmile Group, LLC reported 40 equity positions worth $1.03B in aggregate; its largest disclosed positions were SRRK ($145.40M), KRYS ($116.75M), STOK ($98.13M).
How large is Redmile Group, LLC's portfolio?
Redmile Group, LLC reported $1.03B of long equity holdings across 40 positions as of 2025-Q3. Top-10 holdings account for 68.9% of reported value.
What is Redmile Group, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.